

# JEM Advisory Editorial Board: Increasing diversity

Carl Nathan,<sup>1</sup> Michel C. Nussenzweig,<sup>1</sup> and Teodoro Pulvirenti<sup>2</sup>

<sup>1</sup>Editorial Board Co-Chairs and <sup>2</sup>Executive Editor, *The Journal of Experimental Medicine*

*The Journal of Experimental Medicine* (JEM) Advisory Editorial Board includes over 100 prominent scientists. To ensure that the Advisory Editorial Board covers the diversity of research fields served by the journal, offers the next generation of researchers an opportunity to participate, and improves in gender balance, we welcome to the Board the experts listed below.

Adding new voices and doubling the number of women on the Board are steps in a process that will continue in the years ahead.

We thank the former Advisory Editorial Board members for their invaluable contributions and for remaining members of the JEM community.

List of new Advisory Editors with their institutions

New Advisory Editor name	Institution
Akiko Iwasaki	Yale University, New Haven, CT
Asrar Malik	University of Illinois at Chicago, College of Medicine, Chicago, IL
Bertie Gottgens	Cambridge Institute for Medical Research, Cambridge, England, UK
Charles Mullighan	St. Jude Children's Research Hospital, Memphis, TN
Daniel Geschwind	University of California, Los Angeles, School of Medicine, Los Angeles, CA
Daniel Mucida	The Rockefeller University, New York, NY
David Artis	Weill Cornell Medicine, New York, NY
Denise Monack	Stanford University, School of Medicine, Stanford, CA
Elaine Dzierzak	University of Edinburgh, MRC Centre for Inflammation Research, Edinburgh, Scotland, UK
Emil Unanue	Washington University, St. Louis, MO
Erika Pearce	Max Plank Institute of Immunobiology and Epigenetics, Freiburg, Germany
Florian Greten	Georg Speyer Haus, Frankfurt, Germany
Hanna Mikkola	University of California, Los Angeles, Los Angeles, CA
Helen Su	National Institute of Allergy and Infectious Disease, Bethesda, MD
Hergen Spits	Academic Medical Center, Amsterdam, Netherlands
Jack Parent	University of Michigan, Ann Arbor, MI
Jedd Wolchok	Memorial Sloan-Kettering Cancer Center, New York, NY
Jeffrey Noebels	Baylor College of Medicine, Houston, TX
Jenny Ting	University of North Carolina, School of Medicine, Chapel Hill, NC
Johanna Joyce	University of Lausanne, Lausanne, Switzerland
Joseph Sun	Memorial Sloan-Kettering Cancer Center, New York, NY
Jos Jonkers	Netherlands Cancer Institute, Amsterdam, Netherlands
Laura Pasqualucci	Columbia University, New York, NY
Leonard Zon	Boston Children's Hospital, Boston, MA
Linda Noble-Haeusslein	University of California, San Francisco, San Francisco, CA
Lucy Godley	University of Chicago, Chicago, IL
Luisa Iruela-Arispe	University of California, Los Angeles, Los Angeles, CA
Mikala Egeblad	Cold Spring Harbor Laboratories, Cold Spring Harbor, NY
Miriam Merad	Icahn School of Medicine at Mount Sinai, New York, NY
Nicholas Chiorazzi	The Feinstein Institute for Medical Research, Manhasset, NY
Nicholas Restifo	National Cancer Institute, Bethesda, MD
Pamela Schwartzberg	National Human Genome Research Institute, Bethesda, MD
Patricia Ernst	University of Colorado, School of Medicine, Aurora, CO
Paul Frenette	Albert Einstein College of Medicine, New York, NY
Margaret (Peggy) Goodell	Baylor College of Medicine, Houston, TX
Rino Rappuoli	GlaxoSmithKline Vaccines, Siena, Italy
Robert Siliciano	The Johns Hopkins University, Baltimore, MD
Ross Levine	Memorial Sloan-Kettering Cancer Center, New York, NY
Sayuri Yamazaki	Nagoya City University, Nagoya, Japan
Tirumala Kanneganti	St. Jude Children's Research Hospital, Memphis, TN
Thomas Gajewski	University of Chicago, Chicago, IL
Ulrich Steidl	Albert Einstein College of Medicine, New York, NY
Valerie Weaver	University of California, San Francisco, San Francisco, CA
Virginia Pascual	Weill Cornell Medical College, New York, NY

Correspondence to Teodoro Pulvirenti: [tpulvirent@rockefeller.edu](mailto:tpulvirent@rockefeller.edu)

© 2017 Rockefeller University Press This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms/>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).

